Oric Pharmaceuticals/$ORIC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Oric Pharmaceuticals

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Ticker

$ORIC
Sector
Primary listing

Employees

128

ORIC Metrics

BasicAdvanced
$1.1B
-
-$1.89
1.69
-

What the Analysts think about ORIC

Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.

Bulls say / Bears say

ORIC boosted its cash reserves to $244 million through Q2 2025 financings, extending its cash runway to the second half of 2028 to back Phase 3 milestones. (Reuters)
ORIC entered a clinical supply agreement with Johnson & Johnson to evaluate ORIC-114 with subcutaneous amivantamab for first-line NSCLC with EGFR exon 20 insertion mutations, reducing risk by partnering with a major pharma. (ORIC Pharmaceuticals)
At the 2025 AACR Annual Meeting, ORIC presented preclinical data for ORIC-944 showing synergistic efficacy and longer progression-free survival when combined with AR inhibitors, supporting its best-in-class potential. (GlobeNewswire)
ORIC reported a net loss of $36.4 million in Q2 2025, with basic EPS of –$0.47, pointing to continued unprofitable operations. (Reuters)
The company's shift to prioritize clinical programs included reduced investment in discovery research, narrowing its pipeline and potentially limiting long-term innovation. (Reuters)
As a clinical-stage, pre-commercial company, ORIC reported no revenue in Q2 2025, highlighting its reliance on outside funding instead of product sales. (ChartMill)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

ORIC Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ORIC Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ORIC

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs